**Core Concept**
The question is testing the sensitivity of various cancer types to chemotherapy in advanced stages. Chemotherapy sensitivity refers to the responsiveness of cancer cells to chemotherapeutic agents, which can be influenced by factors such as tumor biology, genetic mutations, and microenvironmental factors.

**Why the Correct Answer is Right**
Chemosensitivity varies among different cancer types, and some are inherently resistant to chemotherapy. For instance, certain types of cancer, like glioblastoma, are known to be relatively resistant to chemotherapy due to their aggressive biology and rapid cell turnover. This resistance can be attributed to the presence of specific genetic mutations, such as mutations in the TP53 gene, which can lead to altered DNA repair mechanisms and reduced effectiveness of chemotherapy.

**Why Each Wrong Option is Incorrect**
* **Option A:** Some cancer types, like acute myeloid leukemia (AML), are highly sensitive to chemotherapy, especially in advanced stages. AML cells often exhibit rapid cell division, making them more susceptible to chemotherapeutic agents.
* **Option B:** Advanced-stage ovarian cancer is generally responsive to chemotherapy, particularly platinum-based agents like carboplatin and paclitaxel. Chemotherapy is a cornerstone of treatment for ovarian cancer, and response rates are often high in advanced stages.
* **Option C:** Glioblastoma, on the other hand, is relatively resistant to chemotherapy, as mentioned earlier. This resistance can lead to poor outcomes in advanced stages, making it a less sensitive cancer type to chemotherapy.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that cancer biology and treatment responses can vary significantly among individuals, even within the same cancer type. Genetic profiling and molecular characterization of tumors can help predict treatment responses and guide personalized therapy.

**Correct Answer:** C. Glioblastoma.